Aptose Biosciences Inc (APTO)

[Tartiaboy]

I think it would be very smart for APTO of out-license LUX for non-cancer indications once they get the dosing set. That said, I see huge synergy with combinations of LUX and TUSP in AML based on the complementary kinome inhibition profiles. Further LUX is likely to find a space in NHL, perhaps DLBCL, especially in combinations.

You need to get past thinking about the proteins as Flt3 inhibitors or BTK inhibitors. Those functions are subsets of their activities.